Keren Mano Tamir
Scientific Strategy Communications & Business Development Head Everads Therapy
Keren Mano Tamir, M.D., MBA trained in medicine and completed two years of ophthalmology residency before pivoting to the biotech industry, inspired by the intersection of medicine and technology. With nearly a decade of experience in biotech, she integrates her clinical background with business and innovation expertise to advance ophthalmic drug delivery. Dr. Mano Tamir has been actively involved across the spectrum of development—ranging from preclinical research and translational work to identifying new applications, guiding clinical studies, and supporting adoption. Her career focus is on moving breakthrough technologies efficiently from bench to bedside.
Seminars
With new device innovations and clinical data now available, suprachoroidal delivery is emerging as a viable, patient-friendly alternative to intravitreal and subretinal injections.
- Understand why biopharma and gene therapy companies are now choosing suprachoroidal delivery to directly target the retina and choroid, overcome the limitations of intravitreal and subretinal injections, and reduce patient burden
- Learn how a tangential suprachoroidal delivery approach with the Everads Injector performed in a first-in-human trial, demonstrating safety, efficacy, and stable IOP with only topical anesthesia
- See how the Everads injector supports a rapid distribution of both small-molecule and gene therapy delivery to the back of the eye, and volumes up to 200µL tolerated in preclinical models
- Discover how the injector’s ease-of-use could support future adoption, with procedures completed in ~40 seconds, no accidental IVTs observed in clinical use, and simplified global training for retinal surgeons and CROs
